Finally, a Highly Actionable Clinical-Grade Genomic Test
The Lifetime Genomic Risk Assessment has demonstrated the ability to identify over 45% of patients at risk for at least one major common disease across 1,000 disease assessments from patients aged 19 to 86.
Panels and Disease Coverage
GenomicMD analyzes nearly two million variants in the genome for our PRS assessment and will be adding your entire exome (all genes) for monogenic analysis.
Common Cancers PRS (10):
Prostate, Breast, Colorectal, Pancreatic, Esophageal, Cervical, Lung, Renal, Melanoma, Non-Melanoma Skin Cancer
Cardiovascular PRS (5):
Coronary Artery Disease (CAD), Abdominal Aortic Aneurysm (AAA), Atrial Fibrillation (AFib), T1D/T2D
Cardiometabolic PRS (5):
T1 Diabetes, T2 Diabetes, Coronary Artery Disease (CAD), Obesity, Chronic Kidney Disease (CKD)
Blood Clotting/VTE:
Venous Thromboembolism (VTE) PRS & monogenic analysis of Factor V Leiden (FVL) and Prothrombin (PGM)
Urology LGRA PRS (2):
Prostate Cancer, Benign Prostatic Hyperplasia (BPH)
All-in-One:
All diseases listed
How is Our Assessment Derived?
- Comprehensive Review: combined impact of polygenic and monogenic into a single analysis
- Polygenic Risk Scores (PRS): adding the independent risk of many, typically millions of single nucleotide polymorphisms (SNPs)
- Rare Pathogenic Mutations (RPM): where one gene causes a clear observed effect where a few variants or genes are correlated to a specific disease or condition, but the occurrence is rare (typically 1-3% of the population) but has a severe correlation to disease risk (coming soon)
- Recurrent Mutations: like Factor V Leiden (FVL), where a single mutation impacts disease moderately but also occurs frequently in the population (>3%)
- Ancestry-Specific: when the peer-reviewed literature supports it, GMD utilizes an ancestry-specific risk assessment approach vs. a pan-ancestry approach
- Validation: our applications are validated on public and more diverse proprietary biobanks
Peer-Reviewed Research Supporting our Science
- Blood Clotting/VTE: Predicting VTE using polygenic and monogenic variants (available by request)
- Blood Clotting/VTE: Identify the risk of blood clotting in cancer patients
- Cardiovascular: Reclassifying the risk of coronary artery disease subjects with borderline or intermediate risk
- Diabetes: Validation distinguishing different types of diabetes
- Diabetes: Clinical utility of polygenic risk scores for diabetes with atypical phenotypes
- Stroke: Combined polygenic scores aid risk assessment of ischemic stroke
- Alzheimer’s: Refining Risk for Alzheimer's Disease Among Heterozygous APOEɛ4 Carriers
